Literature DB >> 10816449

DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity.

G Delogu1, A Howard, F M Collins, S L Morris.   

Abstract

Genetic immunization is a promising new technology for developing vaccines against tuberculosis that are more effective. In the present study, we evaluated the effects of intracellular turnover of antigens expressed by DNA vaccines on the immune response induced by these vaccines in a mouse model of pulmonary tuberculosis. The mycobacterial culture filtrate protein MPT64 was expressed as a chimeric protein fused to one of three variants of the ubiquitin protein (UbG, UbA, and UbGR) known to differentially affect the intracellular processing of the coexpressed antigens. Immunoblot analysis of cell lysates of in vitro-transfected cells showed substantial differences in the degradation rate of ubiquinated MPT64 (i.e., UbG64 < UbA64 < UbGR64). The specific immune response generated in mice correlated with the stability of the ubiquitin-conjugated antigen. The UbA64 DNA vaccine induced a weak humoral response compared to UbG64, and a mixed population of interleukin-4 (IL-4)- and gamma interferon (IFN-gamma)-secreting cells. Vaccination with the UbGR64 plasmid generated a strong Th1 cell response (high IFN-gamma, low IL-4) in the absence of a detectable humoral response. Aerogenic challenge of vaccinated mice with Mycobacterium tuberculosis indicated that immunization with both the UbA64- and UbGR64-expressing plasmids evoked an enhanced protective response compared to the vector control. The expression of mycobacterial antigens from DNA vaccines as fusion proteins with a destabilizing ubiquitin molecule (UbA or UbGR) shifted the host response toward a stronger Th1-type immunity which was characterized by low specific antibody levels, high numbers of IFN-gamma-secreting cells, and significant resistance to a tuberculous challenge.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10816449      PMCID: PMC97537          DOI: 10.1128/IAI.68.6.3097-3102.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

Review 1.  The N-end rule: functions, mysteries, uses.

Authors:  A Varshavsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

2.  Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis.

Authors:  L Brandt; T Oettinger; A Holm; A B Andersen; P Andersen
Journal:  J Immunol       Date:  1996-10-15       Impact factor: 5.422

3.  The immunogenicity of single and combination DNA vaccines against tuberculosis.

Authors:  S Morris; C Kelley; A Howard; Z Li; F Collins
Journal:  Vaccine       Date:  2000-04-14       Impact factor: 3.641

4.  Immunogenicity and protective efficacy of a tuberculosis DNA vaccine.

Authors:  K Huygen; J Content; O Denis; D L Montgomery; A M Yawman; R R Deck; C M DeWitt; I M Orme; S Baldwin; C D'Souza; A Drowart; E Lozes; P Vandenbussche; J P Van Vooren; M A Liu; J B Ulmer
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

5.  Vaccination against tuberculosis by DNA injection.

Authors:  R E Tascon; M J Colston; S Ragno; E Stavropoulos; D Gregory; D B Lowrie
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

6.  Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.

Authors:  G A Colditz; T F Brewer; C S Berkey; M E Wilson; E Burdick; H V Fineberg; F Mosteller
Journal:  JAMA       Date:  1994-03-02       Impact factor: 56.272

Review 7.  Heat shock proteins transfer peptides during antigen processing and CTL priming.

Authors:  P K Srivastava; H Udono; N E Blachere; Z Li
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

8.  Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells.

Authors:  T L Stevens; A Bossie; V M Sanders; R Fernandez-Botran; R L Coffman; T R Mosmann; E S Vitetta
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

9.  Protection to mice afforded by BCG vaccines against an aerogenic challenge by three mycobacteria of decreasing virulence.

Authors:  F M Collins
Journal:  Tubercle       Date:  1985-12

10.  Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis.

Authors:  C Reis e Sousa; R N Germain
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

View more
  29 in total

1.  Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

Authors:  A Weinrich Olsen; L A van Pinxteren; L Meng Okkels; P Birk Rasmussen; P Andersen
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice.

Authors:  Michela Sali; Gabriele Di Sante; Alessandro Cascioferro; Antonella Zumbo; Chiara Nicolò; Valentina Donà; Stefano Rocca; Annabella Procoli; Matteo Morandi; Francesco Ria; Giorgio Palù; Giovanni Fadda; Riccardo Manganelli; Giovanni Delogu
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

3.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.

Authors:  M A Horwitz; G Harth; B J Dillon; S Maslesa-Galic'
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 4.  On the use of DNA vaccines for the prophylaxis of mycobacterial diseases.

Authors:  Kris Huygen
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

5.  Effects of rapid antigen degradation and VEE glycoprotein specificity on immune responses induced by a VEE replicon vaccine.

Authors:  M E Fluet; A C Whitmore; D A Moshkoff; K Fu; Y Tang; M L Collier; A West; D T Moore; R Swanstrom; R E Johnston; N L Davis
Journal:  Virology       Date:  2007-09-27       Impact factor: 3.616

6.  Mucosal vaccination against tuberculosis using inert bioparticles.

Authors:  Rajko Reljic; Laura Sibley; Jen-Min Huang; Ilaria Pepponi; Andreas Hoppe; Huynh A Hong; Simon M Cutting
Journal:  Infect Immun       Date:  2013-08-19       Impact factor: 3.441

7.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

Review 8.  Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.

Authors:  James A Williams; Aaron E Carnes; Clague P Hodgson
Journal:  Biotechnol Adv       Date:  2009-02-20       Impact factor: 14.227

9.  Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis.

Authors:  Steven C Derrick; Charlene Repique; Philip Snoy; Amy Li Yang; Sheldon Morris
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

10.  Targeting myelin proteolipid protein to the MHC class I pathway by ubiquitination modulates the course of experimental autoimmune encephalomyelitis.

Authors:  Diethilde J Theil; Jane E Libbey; Fernando Rodriguez; J Lindsay Whitton; Ikuo Tsunoda; Tobias J Derfuss; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2008-11-15       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.